|
|
||||||||
Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016
High
concentrations of nonesterified fatty acids (NEFA) are a risk factor
for developing type 2 diabetes in Pima Indians. In vitro and in vivo,
chronic elevation of NEFA decreases glucose-stimulated insulin
secretion. We hypothesized that high fasting plasma NEFA would increase
the risk of type 2 diabetes by inducing a worsening of
glucose-stimulated insulin secretion in Pima Indians. To test this
hypothesis, fasting plasma NEFA concentrations, body composition, insulin action (M), acute insulin response (AIR, 25-g IVGTT), and
glucose tolerance (75-g OGTT) were measured in 151 Pima Indians [107
normal glucose tolerant (NGT), 44 impaired glucose tolerant (IGT)] at
the initial visit. These subjects, participants in ongoing studies of
the pathogenesis of obesity and type 2 diabetes, had follow-up
measurements of body composition, glucose tolerance, M, and AIR. In NGT
individuals, cross-sectionally, high fasting plasma NEFA concentrations
at the initial visit were negatively associated with AIR after
adjustment for age, sex, percent body fat, and M (P = 0.03). Longitudinally, high fasting plasma NEFA concentrations at the
initial visit were not associated with change in AIR. In individuals
with IGT, cross-sectionally, high fasting plasma NEFA
concentrations at the initial visit were not associated with AIR.
Longitudinally, high fasting plasma NEFA concentrations at the initial
visit were associated with a decrease in AIR before (P < 0.0001) and after adjustment for sex, age at follow-up, time of
follow-up, change in percent body fat and insulin sensitivity, and AIR
at the initial visit (P = 0.0006). In conclusion,
findings in people with NGT indicate that fasting plasma NEFA
concentrations are not a primary etiologic factor for
-cell failure.
However, in subjects who have progressed to a state of IGT, chronically elevated NEFA seem to have a deleterious effect on insulin-secretory capacity.
-cell; insulin secretion; insulin sensitivity; diabetes; oral
and intravenous glucose tolerance tests; normal glucose tolerance; impaired glucose tolerance
This article has been cited by other articles:
![]() |
G. Boden and M. Laakso Lipids and Glucose in Type 2 Diabetes: What About the {beta}-Cell and the Mitochondria?: Response to Eldor and Raz Diabetes Care, April 1, 2005; 28(4): 986 - 987. [Full Text] [PDF] |
||||
![]() |
G. Boden and M. Laakso Lipids and Glucose in Type 2 Diabetes: What is the cause and effect? Diabetes Care, September 1, 2004; 27(9): 2253 - 2259. [Full Text] [PDF] |
||||
![]() |
J. S. Pankow, B. B. Duncan, M. I. Schmidt, C. M. Ballantyne, D. J. Couper, R. C. Hoogeveen, and S. H. Golden Fasting Plasma Free Fatty Acids and Risk of Type 2 Diabetes: The Atherosclerosis Risk in Communities study Diabetes Care, January 1, 2004; 27(1): 77 - 82. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |